The optimal selection of radiotherapy treatment for hepatocellular carcinoma

Gut and Liver

Volumn 6, Issue 2, 2012, Pages 139-148

  Lee, Ik Jae ^a   Seong, Jinsil ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Radiotherapy

Indexed keywords

FERRITIN ANTIBODY I 131; YTTRIUM 90;

ADVANCED CANCER; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; METASTASIS; PRACTICE GUIDELINE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TOMOTHERAPY; TREATMENT INDICATION;

EID: 84860318042     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2012.6.2.139     Document Type: Review

References (83)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236. (Pubitemid 43112690)
3. Cochrane AM, Murray-Lyon IM, Brinkley DM, Williams R. Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer 1977;40:609-614. (Pubitemid 8177874)
4. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965;93:200-208.
5. Lawrence TS, Tesser RJ, ten Haken RK. An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. Int J Radiat Oncol Biol Phys 1990;19:1041-1047. (Pubitemid 20345178)
6. Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992;23:781-788.
7. Robertson JM, McGinn CJ, Walker S, et al. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys 1997;39:1087-1092. (Pubitemid 27506161)
8. Seong J, Keum KC, Han KH, et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999;43:393-397. (Pubitemid 29091482)
9. Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005;25:1189-1196. (Pubitemid 41782564)
10. Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1143-1150. (Pubitemid 40340909)
11. Park JW; Korean Liver Cancer Study Group and National Cancer Center. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004;10:88-98.
12. Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423.
13. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-219. (Pubitemid 38402113)
14. Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994;106:720-727. (Pubitemid 24064340)
15. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928. (Pubitemid 15228292)
16. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
17. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-215. (Pubitemid 36527122)
18. Seong J, Shim SJ, Lee IJ, et al. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1037-1042.
19. Seong J, Park HC, Han KH, et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 2003;27:30-35. (Pubitemid 37168649)
20. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025-1033. (Pubitemid 29487300)
21. Pressman D, Day ED, Blau M. The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res 1957;17:845-850.
22. Tang ZY, Liu KD, Bao YM, et al. Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection. Cancer 1990;65:211-215.
23. Order SE, Stillwagon GB, Klein JL, et al. Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study. J Clin Oncol 1985;3:1573-1582. (Pubitemid 16199208)
24. Order S, Pajak T, Leibel S, et al. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: An RTOG study. Int J Radiat Oncol Biol Phys 1991;20:953-963.
25. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients. Liver Transpl 2004;10(2 Suppl 1):S107-S110. (Pubitemid 38240109)
26. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S194-S205. (Pubitemid 39423388)
27. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335-345. (Pubitemid 38451976)
28. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81. (Pubitemid 351171043)
29. Kim JK, Han KH, Lee JT, et al. Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res 2006;12:543-548. (Pubitemid 43166147)
30. Sohn JH, Choi HJ, Lee JT, et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology 2009;76:1-9.
31. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: Current status and issues of interest. Int J Radiat Oncol Biol Phys 2001;51:880-914.
32. Cheng JC, Wu JK, Huang CM, et al. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2003;56:229-234. (Pubitemid 36403696)
33. Mackie TR, Holmes T, Swerdloff S, et al. Tomotherapy: A new concept for the delivery of dynamic conformal radiotherapy. Med Phys 1993;20:1709-1719. (Pubitemid 24001191)
34. Mackie TR, Balog J, Ruchala K, et al. Tomotherapy. Semin Radiat Oncol 1999;9:108-117. (Pubitemid 29096027)
35. Cattaneo GM, Dell'oca I, Broggi S, et al. Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC. Radiother Oncol 2008;88:310-318.
36. Widesott L, Pierelli A, Fiorino C, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: Planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys 2008;72:589-596.
37. Lee IJ, Seong J, Koom WS, et al. Selection of the optimal radiotherapy technique for locally advanced hepatocellular carcinoma. Jpn J Clin Oncol 2011;41:882-889.
38. Park HC, Seong J, Han KH, et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002;54:150-155.
39. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003;55:329-336. (Pubitemid 36069090)
40. Seo YS, Kim MS, Yoo SY, et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010;102:209-214.
41. Louis C, Dewas S, Mirabel X, et al. Stereotactic radiotherapy of hepatocellular carcinoma: Preliminary results. Technol Cancer Res Treat 2010;9:479-487.
42. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-664. (Pubitemid 351264363)
43. Cárdenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-225.
44. Cárdenes HR. Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clin Transl Oncol 2009;11:276-283.
45. Dawson LA, Eccles C, Bissonnette JP, Brock KK. Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys 2005;62:1247-1252. (Pubitemid 40884441)
46. Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients. Clin Cancer Res 2005;11:3799-3805. (Pubitemid 40685599)
47. Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 2006;107:591-598. (Pubitemid 44107220)
48. Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for hepatocellular carcinoma: The University of Tsukuba experience. Cancer 2009;115:5499-5506.
49. Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: Preliminary results of a phase II trial. Gastroenterology 2004;127(5 Suppl 1):S189-S193. (Pubitemid 39423387)
50. Kawashima M, Furuse J, Nishio T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839-1846. (Pubitemid 46211361)
51. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917. (Pubitemid 37518510)
52. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S179-S188. (Pubitemid 39423386)
53. Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: Treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79-83. (Pubitemid 23183103)
54. Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: Relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007;18:365-376. (Pubitemid 46616707)
55. Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: Dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 2010;78:1073-1080.
56. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-e453.
57. Takeda A, Takahashi M, Kunieda E, et al. Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity. Hepatol Res 2008;38:60-69. (Pubitemid 350182577)
58. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171. (Pubitemid 34454013)
59. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442. (Pubitemid 36152543)
60. Sakurai M, Okamura J, Kuroda C. Transcatheter chemo-embolization effective for treating hepatocellular carcinoma. A histopathologic study. Cancer 1984;54:387-392. (Pubitemid 14087866)
61. Yu YQ, Xu DB, Zhou XD, et al. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993;71:62-65.
62. Yasuda S, Ito H, Yoshikawa M, et al. Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy. Int J Oncol 1999;15:467-473.
63. Guo WJ, Yu EX. Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Br J Radiol 2000;73:1091-1097.
64. Chia-Hsien Cheng J, Chuang VP, Cheng SH, et al. Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. Int J Cancer 2001;96:243-252. (Pubitemid 33081229)
65. Zeng ZC, Tang ZY, Fan J, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004;10:307-316. (Pubitemid 44403469)
66. Koom WS, Seong J, Han KH, Lee do Y, Lee JT. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys 2010;77:1433-1440.
67. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
68. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009;10:25-34.
69. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005;23:8739-8747. (Pubitemid 46211519)
70. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
71. Yamada K, Izaki K, Sugimoto K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-119. (Pubitemid 36959746)
72. Zeng ZC, Fan J, Tang ZY, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005;61:432-443. (Pubitemid 40164438)
73. Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocel lular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001;16:660-665. (Pubitemid 34188841)
74. Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002;25:189-193. (Pubitemid 34293077)
75. Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-2426. (Pubitemid 40686589)
76. Han KH, Seong J, Kim JK, et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995-1003.
77. Lin CS, Jen YM, Chiu SY, et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006;36:212-217.
78. Cha HJ, Seong JS, Yoon HI, Pyun H, Koom WS. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for locally advanced hepatocellular carcinoma. J Korean Soc Ther Radiol Oncol 2010;28:52.
79. Yoon SM, Kim JH, Choi EK, et al. Radioresponse of hepatocellular carcinoma-treatment of lymph node metastasis. Cancer Res Treat 2004;36:79-84.
80. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005;25:261-265.
81. Nakamura N, Igaki H, Yamashita H, et al. A retrospective study of radiotherapy for spinal bone metastases from hepatocellular carcinoma (HCC). Jpn J Clin Oncol 2007;37:38-43. (Pubitemid 47090721)
82. Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: Prognostic factors and outcome: Brain metastasis from HCC. J Neurooncol 2009;91:307-313.
83. McIntosh A, Hagspiel KD, Al-Osaimi AM, et al. Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. Cancer 2009;115:5117-5125.